📊 PKTX Key Takeaways
Is ProtoKinetix, Inc. (PKTX) a Good Investment?
ProtoKinetix is in critical financial distress with only $607 in cash reserves against $45M in operating losses and zero revenue generation. The company's current ratio of 0.03x indicates severe insolvency with virtually no ability to meet near-term obligations. Unless immediate funding materializes, the company faces imminent financial failure.
Why Buy ProtoKinetix, Inc. Stock? PKTX Key Strengths
- Minimal long-term debt ($0) reduces liability burden
- Pharmaceutical sector allows for R&D losses in development stage
- Small asset base could theoretically be recapitalized through equity funding
PKTX Stock Risks: ProtoKinetix, Inc. Investment Risks
- Cash reserves of $607 are critically insufficient for operations or obligations
- Current ratio of 0.03x indicates severe liquidity crisis and insolvency
- Zero revenue with $24.9M operating losses is unsustainable burn rate
- Negative operating cash flow of -$135.9K indicates ongoing value destruction
- No insider trading activity suggests lack of confidence or abandoned operations
Key Metrics to Watch
- Cash position (imminent insolvency concern)
- Revenue generation initiation and trajectory
- Operating cash flow trend
- Dilution from emergency equity financing
ProtoKinetix, Inc. (PKTX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
PKTX Profit Margin, ROE & Profitability Analysis
PKTX vs Healthcare Sector: How ProtoKinetix, Inc. Compares
How ProtoKinetix, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is ProtoKinetix, Inc. Stock Overvalued? PKTX Valuation Analysis 2026
Based on fundamental analysis, ProtoKinetix, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
ProtoKinetix, Inc. Balance Sheet: PKTX Debt, Cash & Liquidity
PKTX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: ProtoKinetix, Inc.'s revenue has declined by 100% over the 5-year period, indicating business contraction. The most recent EPS of $-0.01 indicates the company is currently unprofitable.
PKTX Revenue Growth, EPS Growth & YoY Performance
PKTX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2014 | N/A | -$14.0K | N/A |
| Q2 2014 | N/A | -$69.3K | N/A |
| Q1 2014 | N/A | -$85.3K | N/A |
| Q3 2013 | N/A | -$42.0K | N/A |
| Q2 2013 | N/A | -$40.2K | N/A |
| Q1 2013 | N/A | -$66.4K | N/A |
| Q3 2012 | N/A | -$44.2K | N/A |
| Q1 2012 | N/A | -$66.4K | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
ProtoKinetix, Inc. Dividends, Buybacks & Capital Allocation
PKTX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for ProtoKinetix, Inc. (CIK: 0001128189)
📋 Recent SEC Filings
❓ Frequently Asked Questions about PKTX
What is the AI rating for PKTX?
ProtoKinetix, Inc. (PKTX) has an AI rating of STRONG SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.
What are PKTX's key strengths?
Claude: Minimal long-term debt ($0) reduces liability burden. Pharmaceutical sector allows for R&D losses in development stage.
What are the risks of investing in PKTX?
Claude: Cash reserves of $607 are critically insufficient for operations or obligations. Current ratio of 0.03x indicates severe liquidity crisis and insolvency.
What is PKTX's revenue and growth?
ProtoKinetix, Inc. reported revenue of $0.0.
Does PKTX pay dividends?
ProtoKinetix, Inc. does not currently pay dividends.
Where can I find PKTX SEC filings?
Official SEC filings for ProtoKinetix, Inc. (CIK: 0001128189) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is PKTX's EPS?
ProtoKinetix, Inc. has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is PKTX a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, ProtoKinetix, Inc. has a STRONG SELL rating with 95% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is PKTX stock overvalued or undervalued?
Valuation metrics for PKTX: ROE of -109.3% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy PKTX stock in 2026?
Our dual AI analysis gives ProtoKinetix, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is PKTX's free cash flow?
ProtoKinetix, Inc.'s operating cash flow is $-135.9K, with capital expenditures of N/A.
How does PKTX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -109.3% (avg: 15%), current ratio 0.03 (avg: 2).